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Abstract An increase in autoimmune diseases poses a
socioeconomic challenge worldwide. Predisposing genetic
risk has been identified, yet environmental factors make up
a significant part of the risk in disease initiation and
propagation. Next to improved hygiene and a gross
reduction of infections, changes in dietary habits are one of
the most evident Western lifestyle factors potentially
associated with the increase in autoimmune diseases.
Growing evidence suggests that particularly a typical
‘Western diet’, rich in saturated fat and salt and related
pathologies can have a profound impact on local and sys-
temic immune responses under physiologic and
autoimmune conditions such as in multiple sclerosis (MS).
In this review, we discuss recent findings on environmental
factors influencing autoimmunity with an emphasis on the
impact of ‘Western diet’ on immune homeostasis and gut
microbiota in MS.
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Introduction
The common cause for autoimmune diseases, such as
multiple sclerosis (MS), type-1 diabetes (T1D), rheumatoid
arthritis (RA) or inflammatory bowel disease (IBD), is
suspected to be the loss of tolerance to self. Initiating
events are mostly unknown but may be associated with a
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responses, including loss of costimulatory control by anti-
gen presenting cells (APC) and ‘‘molecular mimicry’’,
which causes immune cells recognizing a certain extrinsic
antigen to react also to structurally similar self-antigens
[1]. Once an immune reaction is initiated, massive invasion
of immune cells accompanied by a systemic/humoral
immune response leads to tissue damage resulting in
exposure of additional self-antigens [1, 2]. Although pre-
disposing genetic risk factors have been identified for
various autoimmune diseases, it is understood that they
account only for a fraction of the overall disease [3, 4].
Hence, the remaining risk component of autoimmune dis-
eases such as MS must be related to exogenous factors.
Research efforts of the past decades confirm this finding,
and it is now well accepted that the etiology of many
autoimmune diseases involves environmental factors that
act on top of genetic susceptibility profiles [3, 5, 6]. The
increasing incidence of autoimmune diseases with a high
prevalence in Western countries [7, 8] and the rapid evo-
lution of MS in former low prevalence countries like Japan
[9] nurture multiple explanatory concepts around environ-
mental triggers. The so-called hygiene hypothesis aims to
explain the increase in autoimmunity in industrialized
countries by linking the decrease of infection rates and the
increase in autoimmune diseases to a general improvement
of hygiene standards [10].
Besides infection, there are many more environmental
factors that have been proposed to promote autoimmune
diseases, like MS, including climate, stress, occupation,
cigarette smoking, and diet [11]. Of note, the consumption of
‘Westernized food’, including high salt, high fat, high pro-
tein, and high sugar intake, has already been associated with
increasing prevalence in various diseases [12, 13]. The
change of dietary habits has been under intensive investi-
gation, revealing a direct influence on immune homeostasis
and on bacterial communities colonizing the gastrointestinal
tract (GIT) [14] and the gutmicrobiota is tightly connected to
the immune system and highly involved in immune regula-
tory processes [15]. IBD has been associated with shifts and
variety reduction in the microbiome. This observation has
also been made in other autoimmune diseases not directly
associated with the GIT [12, 16]. However, there is still little
understanding on the mechanisms linking environmental
factors to disease mechanisms, genetic predisposition, and
the immune system. Gaining further insight into the influ-
ence of environment andmicrobiota on immune homeostasis
will be a powerful source for a better understanding of the
rising incidence of autoimmune pathologies with the aim to
provide novel approaches for therapeutic treatment and
prevention strategies.
This review will, therefore, discuss recent developments
in research linking the environment to autoimmune diseases
with an emphasis on the nexus of immune cells, dietary
components, and gut microbiota. Thereby, we highlight the
role of CD4? T lymphocytes in MS, especially with respect
to the importance of balancing effector and regulatoryT cells
for maintenance of immune homeostasis.
Immune cells in multiple sclerosis
Worldwide, there are an estimated 2.5 million patients
suffering from MS with women twice as frequently
affected as men [17]. MS is a progressive demyelinating
disease characterized by disseminated central nervous
system (CNS) lesions, most likely caused by an autoim-
mune response to CNS self-antigens [18]. Pathologically,
perivascular inflammatory infiltrates in brain, optic nerve,
and spinal cord dominate during the early phases of the
disease. These infiltrates contain mononuclear immune
cells, such as lymphocytes (CD4? and CD8? T cells as
well as B cells), monocytes, and macrophages, and form
so-called plaques, the end stage of inflammation, charac-
terized by demyelination, astrogliosis, and neuronal as well
as axonal degeneration [5, 19, 20]. Dendritic cells (DCs)
have been shown to play a critical role in immune invasion
of the CNS by presenting antigen to activated autoreactive
T cells [21, 22]. In addition, the activation of microglia and
macrophages plays an essential role in the pathogenesis of
the disease [23]. Recent studies, demonstrating the pres-
ence of inflammatory cells and their products in CNS
lesions, led to the generally accepted hypothesis that at
least relapsing-remitting MS is triggered by pathogenic
CD4? T cells reactive against myelin constituents
[5, 19, 20]. Besides these, several other cells of the innate
and adaptive immune system are involved in the patho-
genesis of MS. For instance, CD8? T cells were shown to
directly damage axons by the secretion of granzyme B and
perforin, [24] and macrophages can contribute to tissue
damage by releasing toxic molecules like nitric oxide,
oxygen radicals and proinflammatory cytokines [25]. Also
B cells [26–28], as well as innate lymphoid cells (ILCs)
[29], c/d T cells [30] and NK cells [31] play distinct
important roles in the autoimmune response. In particular,
the recently discovered ILCs, which are tissue-resident
lymphoid cells that lack specific antigen receptors, gained
interest as new targets for modulating immune tolerance in
autoimmune diseases like MS [29]. ILCs have been rec-
ognized for their importance in mediating the interplay
between microbiota and the immune system [32], and the
non-cytotoxic ILC1, ILC2, and ILC3 show a striking
resemblance to CD4? T cell subsets with respect to
development and function [33, 34].
Many data on the immunopathology of MS stem from
experimental autoimmune encephalomyelitis (EAE), an
animal model mimicking several aspects of the disease
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[35–37]. EAE is most commonly induced in rodents by the
immunization with myelin peptides (e.g., MOG, myelin
oligodendrocyte glycoprotein) and adjuvant [38] or the
transfer of myelin-reactive T cells [39]. The resulting T
cell-mediated acute autoimmune reaction against myelin in
the CNS induces similar symptoms to those seen in MS. It
was thus initially shown in EAE models that CD4? T
helper (Th) cells play a key role in MS. MS was first
thought to be a Th1 cell-mediated autoimmune disease,
with interferon gamma (IFN-c) assuming a pathogenic
role, while Th2 cells producing primarily interleukin (IL)-4
or IL-10 exert a modulatory function with a protective role
[40]. After the identification of the relevance of IL-23 in
EAE, subsequent work showed that also Th17 cells are
involved in the pathogenesis of the disease, since IL-23 is a
critical growth factor for this cell subset [41, 42].
Th17 cells frequently occur in the intestine, playing a
particularly important role in the intestinal immune home-
ostasis by providing defense against extracellular bacteria
and clearance of pathogens [43]. Depending on their phys-
iological role, Th17 cells are exposed to environmental
factors and could, therefore, be influenced by nutritional
components. Together with Th1 cells, Th17 cells are
believed to be the main constituents of the CD4? T effector
subset that drives disease pathology in T cell-dependent
autoimmune diseases [44]. However, due to the fact that
Th17 cells are associated with several autoimmune diseases,
recent investigations often focus on this Th cell subset [44].
In EAE studies, IL-17 deficient mice showed delayed and
reduced symptoms, but no complete protection [45, 46].
More recent studies found that the pathogenicity of Th17
cells additionally depends on the IL-23-induced production
of the cytokine granulocyte macrophage colony-stimulating
factor (GM-CSF), probably explaining the incomplete pro-
tection from EAE in IL-17-deficient mice [47, 48]. The
importance of Th17 cells was also linked toMS, as lesions of
MS patients contained an increased frequency of IL-17-
producing CD4? T cells [49]. Moreover, it was found that
Th17 cells are able to cross the inflamed blood–brain barrier
and secrete the proinflammatory cytokine IL-17A [50]. A
recent study showed that in particular Th17 instead of Th1
responses were absent in patients with MS disease abroga-
tion after hematopoietic stem cell transplantation [51],
confirming the pivotal role of Th17 cells in MS.
In contrast to effector T cells, regulatory T cells (Tregs)
play a central role in immunoregulatory reactions and
suppression of autoreactive immune cells. Once activated,
forkhead box P3 (FoxP3) positive Tregs exert their sup-
pressive functions via the release of anti-inflammatory
cytokines like IL-10 and transforming growth factor
(TGF)-b in addition to cell–cell contact-dependent mech-
anisms [52]. In EAE, adoptive transfer of Tregs improved
disease symptoms, while ablation led to worsening of
disease [52]. Importantly, an impairment of regulatory T
cell function is frequently observed in patients with
autoimmune diseases like MS, and it is believed to be a
major cause for disruption of immune homeostasis, further
contributing to autoimmune reactivity [2, 52]. The loss of
Treg suppressive capacity might be related to the potential
of Tregs to convert into Th1-like Tregs, secreting IFN-c
[53–55], as well as Th17-like Tregs, secreting IL-17 with a
proinflammatory potential [56–59]. In MS patients, IFN-c-
secreting Tregs were found to be increased [60] and Tregs
displayed lower expression levels of FoxP3 and an
impaired suppressive capacity [2, 52, 61–63]. It is thus well
accepted that the balance between T effector cells and Treg
subsets plays a major role in autoimmune diseases like MS.
Environment and its link to MS
Genetic variants influencing susceptibility or protection
from autoimmune diseases like MS have been explored in
studies of twin concordance [64], familiar clustering and
genome wide associations studies (GWAS) [65]. Genes
account for roughly 25–30 % inheritability in monozygotic
twins, and as in the majority of autoimmune diseases,
variants of the human leukocyte antigen (HLA) complex
provide a strong susceptibility for MS. Especially, the
HLA-DRB1*1501 allele is associated with a highly ele-
vated risk for MS development, displaying a sixfold risk
increase in homozygous carriers [65]. In addition, a num-
ber of immune-related risk-alleles have been established
independently of the HLA-locus, affecting in particular
CD4? T cell subset responses [66, 67]. Among the iden-
tified genes are, for instance, the IL-2 and IL-7 receptors,
both genes playing a critical role for Tregs and Th effector
cells [66, 67]. Moreover, predisposing variants for MS
have been found for the Th17/IL-23 axis, supporting a role
for Th17 cells in disease development [66]. Similar studies
have also suggested an increased susceptibility caused by
variants of CD86, an important coreceptor for T cell
stimulation expressed by DCs, supporting the important
role of DC/T cell interaction for MS [65]. A genetic link to
B cell function and MS is for instance based on risk vari-
ants in the CD40 and CXCR5 genes, encoding for a surface
protein inducing B cell activation and differentiation and a
chemokine receptor expressed on B and T cells [28].
GWAS studies have even identified risk association with
genes that are important for current and new MS therapies
including vascular cell adhesion molecule 1 (VCAM1), as
well as genes related to the crucial environmental factor
vitamin D [65]. Nevertheless, the large amount of data on
genetic predisposition for autoimmune diseases can, in
most of the cases, only explain a part of the disease risk,
supporting the view that the increasing prevalence of MS is
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triggered in addition by environmental factors. Epidemio-
logical studies have shown a striking trend of MS toward
higher prevalence with increasing latitude and an increase
in disease incidence in developed countries [7, 8]. Several
theories have aimed to explain these observations. Since
exposure to sunlight is the main source for vitamin D
synthesis in humans, a lower sunlight exposure in high-risk
regions such as Northern Europe results in a decreased
generation of vitamin D. In fact, patients with MS were
found to have lower blood levels of vitamin D [68, 69] and
also in other autoimmune diseases, low vitamin D levels
may represent an emerging risk factor [70, 71]. Studies on
the effect of vitamin D in autoimmunity suggest an
immunomodulatory capacity with anti-inflammatory action
[72, 73]. Moreover, UVB light increased levels of tolero-
genic DCs and Tregs while reducing effector T cell counts
in MS patients [74]. In addition to sunlight, fatty fish could
be a dietary source of vitamin D, and fish consumption
correlated with lower MS prevalence in coastal areas [75].
However, the recent OFAMS study failed to detect any
influence of fish oil on the course of MS [76]. Nevertheless,
there is an increasing amount of data demonstrating the
positive role of vitamin D or other vitamins like biotin [77]
in MS, as summarized elsewhere in depth [78–80].
Furthermore, the hygiene hypothesis states that individ-
uals not exposed to certain infections early in life but
growing upwith improved hygienemay develop a hyperalert
immune system, favoring the occurrence of autoimmune
diseases [10, 81]. While according to the hygiene hypothesis
some infectious agents may be protective, others may
increase the risk, such as Epstein–Barr virus (EBV) which is
associated with MS especially when infection takes place in
late adolescence [5]. A potential explanation for that might
be the similarity of the EBV nuclear antigen (EBNA)-1 to
myelin surface proteins, leading to crossreactivity of adap-
tive immune cells [82]. Interestingly, T cells specific to
EBNA-1 display a significantly higher frequency as well as a
broader specificity in MS patients than in healthy controls
[83]. Although associations between MS and EBV infection
have been well investigated, the role of EBV in MS pathol-
ogy remains unclear as further studies could not demonstrate
latent or active EBV infection in active MS lesions [84].
Infections that might confer a protective effect to the host are
colonizations of the GIT by parasitic worms. Different
studies have shown that helminths may affect the host’s
immune response by the promotion of an anti-inflammatory
environment [85, 86]. Based on this, the possibility of
treating MS with helminths has already been explored in
animal models [87–89] and also phase 1 clinical trials [90].
In line with these findings, the fact that colonization of the
GIT by parasitic worms has decreased over the past decades
in industrialized countries [91] possibly contributes to an
increasing MS prevalence.
The gut and its microbiota recently gained a lot of
attention in various fields of research. The human gut
microbiome is expected to consist of more than 1014 bac-
terial cells from about 500–1000 species and helps the host
to maintain the body in homeostasis [92]. The first exposure
to the human microbiome occurs during birth, and breast
milk or formula feeding further influences the colonization
of the new born’s own gut microbiome [93–95]. During a
lifetime, the human gut is recolonized permanently over the
years with dominating bacterial orders, such as Firmicutes
and Bacteroidetes, and other bacteria found in minor
amounts, creating a unique human gut microbiota for each
individual [16]. The human microbiota reaches maximum
diversity at adolescence and can then be stable for years. A
large amount of physiological functions, such as food
digestion (providing fermentation products) and competi-
tion with potential pathogens, have been described for the
commensal gut bacteria [96, 97]. Besides this, a vast col-
lection of data points out that the gut microbiota is essential
for the proper function of our immune system and meta-
bolism and thus has a strong impact on human’s health.
Indeed, changes in the gut microbiota have been observed in
several diseases such as IBD [98], allergies [99], and asthma
[100–102]. Those changes are induced by many factors,
such as diet, stress or medication, and can lead to a so-called
dysbiosis [103, 104]. A common consequence of dysbiosis
is the alteration of the mucosal immune system leading to a
rise of gut inflammation and alterations of intestinal
immunity [105]. It was shown that a dysbiotic microbiome
could lead to Treg deficiency and an activation of proin-
flammatory Th17 cells [106, 107]. While not expecting a
direct correlation between the gut and brain autoimmunity,
EAE studies indicate that the microbiota might play a role
in MS as well. For instance, germ-free mice were shown to
be protected from EAE induction, and using transgenic
mice, Berer and colleagues could show that gut bacteria are
a necessary prerequisite to induce a relapsing-remitting
autoimmune disease [108]. Consistent with this, oral
antibiotic treatment reduced and modulated bacterial pop-
ulations in wild-type mice and, thereby, significantly
ameliorated EAE onset and severity [109]. This effect was
correlated with an increase in IL-10 producing Tregs,
mainly induced by polysaccharide A of Bacteroides fragilis
[110, 111]. Similar to Tregs, Th17 cells could be influenced
by the gut microbiota. It was demonstrated that distinct
species of commensal bacteria, namely, segmented fila-
mentous bacteria (SFB), can specifically induce Th17 cells
[112]. It was further shown that the induction of these cells
could be indirectly influenced by luminal adenosine
triphosphate (ATP) secreted from bacteria [113]. Moreover,
the recently described gut–brain-axis may further support a
possible link between gut microbiota and autoimmunity
[114].
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In addition to direct effects of the microbiota, also
dietary changes in association with a microbiota modula-
tion are likely to be linked with the increasing incidences
of autoimmune disorders [115]. It was shown that a
‘Western diet’ increases inflammation and might nega-
tively affect the gut-immune homeostasis. In contrast, low-
calorie diets based on fruits, fish and vegetables downreg-
ulate proinflammatory molecules and restore or maintain a
healthy symbiotic gut microbiota [116]. For instance,
plant-derived nutrients were found to be associated with an
anti-inflammatory potential by acting as ligands of the aryl
hydrocarbon receptor (AhR) [117, 118]. AhR acts as a
transcription factor in a variety of immune cells, including
Th17 and Tregs, and has been associated with suscepti-
bility as well as prevention of autoimmune diseases
depending on its ligands [107, 117, 118]. In that matter,
indole-3-carbinol, deriving from crucifers such as broccoli,
has been shown to suppress the production of proinflam-
matory cytokines [118, 119], whereas the tryptophan-
derived AhR ligand FICZ (6-Formylindolo(3,2-b)car-
bazole) specifically increases the Th17 population and,
therefore, worsens EAE severity [107]. Another plant-
derived component supporting the induction of Tregs is
retinoic acid (RA). RA is metabolized from vitamin A,
which is derived from carotenoids in plants and as retinol
from animals [118]. The highly metabolically active
intermediate product all-trans RA (ATRA) can be gener-
ated by mucosal DCs potent in inducing and maintaining
regulatory T cells [120, 121]. Nutrients, mostly discussed
as risk factors in autoimmunity, are related to a ‘Western
diet’. In that matter, especially, changes in the gut micro-
biome in association with diets rich in fat and salt have
gained increasing attention during recent years and are
discussed as potential risk factors for MS (Fig. 1).
Fatty acids
Integral components of the daily diet that have recently
been linked to autoimmunity via changes in the gut
microbiota are fatty acids. Excessive fat intake, in general,
is a prominent factor inducing obesity. Associations
between obesity and MS have already been demonstrated,
displaying a positive correlation between body mass index
and the risk of developing MS, especially at younger ages
[122]. Obesity, defined by the inadequate accumulation of
Fig. 1 Schematic diagram displaying the nexus between ‘Western diet’, gut microbiota, T cells, and autoimmunity
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white adipose tissue (WAT), can lead to a state of systemic
inflammation called ‘‘metaflammation’’. Metaflammation
occurs, because WAT is not only involved in energy
storage, but also functions as an endocrine organ secreting
proinflammatory tumor necrosis factor (TNF)-a, IL-6 or
leptin. The latter in particular is a cytokine-like hormone
profoundly influencing T cell responses in EAE [123–125].
Leptin was shown to enhance phagocytosis and cytokine
secretion in macrophages and to promote CD4? T cell
proliferation and survival [126], favoring Th1 and Th17
reactions while inhibiting Treg responses [125–127]. In
MS patients, monocytes and T cells present in MS lesions
and patient-derived cerebrospinal fluid (CSF) both highly
express leptin and leptin receptor [128, 129]. However, MS
incidence is not necessarily accompanied by weight gain,
thus suspecting a direct effect of fatty acids on immunity.
Fatty acids, subdivided into saturated and unsaturated fatty
acids, were first correlated with MS in the 1950s
[130, 131]. More recent work related x-3 polyunsaturated
fatty acids (PUFAs) to anti-inflammatory effects [132]. In
contrast, x-6 PUFAs are precursors of proinflammatory
eicosanoids that may promote the activation of the Th17
pathway [133] and are thus suspected to play a detrimental
role in a variety of diseases. Studies in the EAE model
demonstrated saturated fats to be a risk or beneficial factor
depending on their chain length [134]. The increased intake
of medium- and long-chain fatty acids (MCFA and LCFA)
by the consumption of an experimental ‘Western diet’ was
shown to exacerbate autoimmunity in the CNS [134]. This
was due to an increased infiltration of Th1 and Th17 cells
in the spinal cord. In vitro, the differentiation of murine and
human CD4? T cells into Th1 and Th17 cells was signif-
icantly increased by the addition of LCFAs. In parallel, the
generation of Tregs was suppressed, coinciding with a
decreased secretion of anti-inflammatory cytokines. In
murine EAE, diets rich in LCFA were shown to modulate
the microbiome, such that naı¨ve CD4? T cells are exposed
to increased LCFA in the small intestine, thus inducing
more proinflammatory T cell responses [134].
Short-chain fatty acids (SCFA) with chain lengths
reaching from one to five C atoms mostly occur in the gut
as fermentation products of dietary fibers by commensal
bacteria [135]. A decrease in SCFA has been observed in
patients with IBD [99, 136]. In MS patients, levels of
Clostridia clusters XIVa and IV were shown to be reduced
[137], both formed by diverse bacterial species that are
able to produce SCFA such as butyrate [138, 139]. Buty-
rate displays anti-inflammatory properties, probably
indicating that a reduction of these microbes in MS patients
may be associated with disease [137–140]. Most data dis-
cussing the mechanism for the effect of SCFA demonstrate
the involvement of Tregs. In a murine model of IBD, the
administration of acetate (C2:0), propionate (C3:0) or
butyrate (C4:0) increased the level of Tregs in the gut
[136, 141]. In addition, the administration of butyrate to
germ-free mice mimicked the effect of Clostridium colo-
nization and increased Treg levels in colon lamina propria
[142]. Investigating the effects of SCFA in the EAE model
also revealed an increase of Tregs, while suppressing the
differentiation of Th17 cells [134]. In EAE, feeding pro-
pionate ameliorated the disease by promoting Tregs in the
small intestine. As a possible mechanism for how propi-
onate might regulate the differentiation of Tregs is the
acetylation of histone H3. SCFA, most potently butyrate,
were shown to function as histone deacetylase inhibitors,
maintaining acetylation of genes important for Treg func-
tion, such as Foxp3 [141–143]. Whether this in vitro effect
could also explain the in vivo amelioration of EAE remains
unclear. However, synthetic small inhibitors of histone
deacetylases have already been shown to decrease inflam-
mation in animal models of arthritis, IBD, asthma,
diabetes, cardiovascular diseases, and MS [143]. Thus,
SCFA as naturally occurring nutrients [144] or fermenta-
tion products may have a possible therapeutic value for
autoimmune diseases like MS by potentially triggering the
production of anti-inflammatory Tregs.
Salt
Another typical hallmark of ‘Westernized food’ is the high
content of sodium chloride (NaCl). In particular, processed
or so-called ‘fast foods’ may contain significantly more
NaCl than homemade meals [145]. Recent literature links
this high sodium intake to cardiovascular diseases [146],
cancer [147], chronic inflammation [148], and also
autoimmune diseases [6, 149, 150]. It was demonstrated
that primary and secondary lymphoid organs, such as the
thymus and lymph nodes, show increased hypertonicity in
comparison to the blood [151], indicating that immune
cells have to cope with these changes when infiltrating
peripheral tissues or during activation in secondary lym-
phoid organs. Studies dating back in the early 1990s have
demonstrated that the activation of innate and adaptive
immune cells under hypertonic conditions could enhance
immune function, and monocytes were shown to get highly
proinflammatory [152], while T cell lines were shown to
secrete less anti-inflammatory factors and to produce, for
instance, more TNF-a [153]. Moreover, it was recently
shown that high salt conditions, mimicking in vivo situa-
tions in the tissue after a high salt diet, enhanced the
activation of classical M1 macrophages, and increased the
expression of proinflammatory mediators [154–156]. In
contrast to this, excess salt diminished the activation of the
so-called M2 macrophages (M(IL-4 ? IL-13)) and
decreased their ability to suppress effector T cell
4616 S. Jo¨rg et al.
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proliferation [157]. Similar to cells of the innate immune
system, raising the sodium concentrations in vitro also
affected adaptive immune cells and promoted the differ-
entiation of murine and human Th17 cells with a
pathogenic phenotype, displaying increased expression of,
e.g., CSF2 and IL-23R [158, 159]. It was demonstrated that
this effect was linked to p38/mitogen-activated protein
kinase (MAPK), nuclear factor of activated T cells 5
(NFAT5), and serum- and glucocorticoid-regulated kinase-
1 (SGK1) dependent pathways. The fact that in particular
pathogenic Th17 cells with a similar phenotype are
involved in autoimmune diseases indicates that a high salt
diet may represent a previously unrecognized environ-
mental risk factor for autoimmunity. Indeed, in the EAE
model, a high salt diet augmented disease onset and
severity [158, 159]. Exacerbated disease was accompanied
by increased induction of Th17 cells and heightened
numbers of CNS infiltrating pathogenic Th17 cells. More
recent work focusing on the effects of sodium chloride on
regulatory immune cells provided evidence that high salt
conditions almost completely block the suppressive func-
tion of human and murine Tregs in vitro and in vivo. High
amounts of salt induced Th1-like Tregs, secreting IFN-c in
an SGK1-dependent manner [160]. In MS patients, a
recently published observational study demonstrated a
heightened disease activity and enhanced inflammation in
subjects with an increased dietary sodium intake [149].
However, direct human data on effects of high salt intake
on the immune system are still sparse. A few available
studies indicate a heightened immune activation in asso-
ciation with excess salt intake. In particular, the
composition of monocyte subsets was shown to be shifted
towards higher numbers of proinflammatory monocytes by
a short-term increase in dietary salt intake [161]. Similarly,
a recent longitudinal study observed a striking correlation
of monocyte numbers and function with salt-intake levels.
The consumption of a high salt diet was paralleled by
higher monocyte counts and a significant increase in IL-6
and IL-23 production, whereas the secretion of IL-10 was
decreased [162]. Intriguingly, IL-6 and IL-23 are major
inducers of Th17 cells also in humans. Novel strategies to
investigate the body’s sodium content recently showed that
a high salt diet is accompanied by a periodical storage of
sodium in skin interstitium and the muscle [163–165]. This
process represents a new regulatory mechanism indepen-
dent from water retention and sodium clearance by the
kidney. Instead, this extra-renal sodium clearance was
shown to involve the immune system. Skin-resident mac-
rophages, activated in an NFAT5-dependent manner,
secrete vascular endothelial growth factor c (VEGF-C), a
growth factor for lymphatic vessels and, thereby, inhibit
the development of salt-mediated hypertension [164]. Ini-
tial studies, measuring the sodium content in humans by
23Na-MRI, revealed this specific accumulation of sodium
in the skin and muscle [163, 166]. The concept that higher
interstitial sodium content via increases in dietary salt
intake may drive proinflammatory responses of the innate
immune system, promoting Th17 cell induction was
recently supported by a study of Medzhitov and colleagues.
In this study, it was shown that macrophages could sense
hypertonic conditions through the caspase-1 pathway,
thereby promoting Th17 cell induction by heightened IL-
1b secretion [167]. In line with these findings, Jantsch et al.
demonstrated that sodium, which accumulated at the site of
skin infections, was able to boost proinflammatory mac-
rophage responses in a p38/MAPK and NFAT5-dependent
manner [156]. In summary, these data indicate that the
sodium balance may affect innate and adaptive immune
function and homeostasis at various levels. Salt intake,
therefore, might represent an environmental risk factor,
which may influence autoimmunity by promoting proin-
flammatory and blocking anti-inflammatory immune
responses. However, it remains to be seen how significant
these effects are for human autoimmunity. It is also likely
that the genetic architect could play a role here, as recently
indicated by an EAE study [168]. Moreover, alterations in
the gut microbiota may indirectly contribute to the
observed effects of altered immune function and disease
[2, 6].
Conclusion
Increasing research efforts indicate that nutritional factors
have the capability to potently modulate autoimmune
responses and inflammation. Sodium chloride and saturated
fatty acids have been implicated as risk factors in many
diseases, such as stroke, hypertension, cardiovascular dis-
eases, chronic inflammation and autoimmunity. It is thus
not surprising that there is growing interest in special diets
as add-on therapies to conventional therapeutics. Although
no long-term clinical trials currently exist, the data dis-
cussed above suggest that the impact of components of the
daily diet like saturated fats and sodium on inflammatory
processes and autoimmunity should be further investigated.
The gut as the main absorption interface for nutritional
components displays the most prominent anatomic site that
links diet and disease. Recent studies have already sug-
gested a role for the gut microbiome in a number of
diseases, including T1D, IBD, and obesity, and present
further evidence that the gut microbiome may also play a
role in diseases affecting the CNS, such as MS. The impact
of gut microbiota and its metabolites on the mucosal
immune system was shown to not only affect the gut
environment, but also to modulate extra-intestinal immune
responses by influencing the balance of pro- and anti-
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inflammatory T cell subsets. Modifying the gut microbiota,
either directly or indirectly through dietary factors, might
thus be a potential therapeutic option for the treatment of
various diseases, including MS. Promoting the induction of
anti-inflammatory Tregs and reducing pathogenic Th17
cell responses might represent here the most promising
strategy in the context of autoimmunity.
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